The LncRNA AK018453 regulates TRAP1/Smad signaling in IL-17-activated astrocytes: A potential role in EAE pathogenesis

Qingxiu Zhang1,2,3 | Ying Yang1 | Yingyu Chen1 | Yifan Wang1 | Suping Qin1 | Ruixue Lv1 | Menglu Zhou1 | Qian Yu1 | Xiangyang Li1 | Xiaocui Li1 | Xiaotian Wang1 | Hongjuan You1 | Yugang Wang1 | Feng Zhou1 | Xiaomei Liu1

1Jiangsu Key Laboratory of Immunity and Metabolism, Department of Pathogen Biology and Immunology and Laboratory of Infection and Immunity, Xuzhou Medical University, Xuzhou, Jiangsu, China
2Department of Neurology of Drum Tower Hospital, Medical School and the State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing, China
3Department of Neurology, Nanjing Drum Tower Clinical College of Xuzhou Medical University, Nanjing, China

Abstract
The pro-inflammatory cytokine interleukin 17 (IL-17), that is mainly produced by Th17 cells, has been recognized as a key regulator in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Reactive astrocytes stimulated by proinflammatory cytokines including IL-17 are involved in blood brain barrier destruction, inflammatory cells infiltration and spinal cord injury. However, the role of long non-coding RNAs (lncRNAs) induced by IL-17 in the pathogenesis of MS and EAE remains unknown. Herein, we found that an IL-17-induced lncRNA AK018453 promoted TGF-β receptor-associated protein 1 (TRAP1) expression and Smad-dependent signaling in mouse primary astrocytes. Knockdown of AK018453 significantly suppressed astrocytosis, attenuated the phosphorylation of Smad2/3, reduced NF-κB p65 and CBP/P300 binding to the TRAP1 promoter, and diminished pro-inflammatory cytokine production in the IL-17-treated astrocytes. AK018453 knockdown in astrocytes by a lentiviral vector in vivo dramatically inhibited inflammation and prevented the mice from demyelination in the spinal cord during the progression of EAE. Together, these results suggest that AK018453 regulates IL-17-dependent inflammatory response in reactive astrocytes and potentially promotes the pathogenesis of EAE via the TRAP1/Smad pathway. Targeting this pathway may have a therapeutic potential for intervening inflammatory demyelinating diseases.

Abbreviations: CNS, central nervous system; Ctrl-shRNA, scrambled control shRNA; CXCL10, C-X-C motif chemokine 10; EAE, experimental autoimmune encephalomyelitis; GFAP, glial fibrillary acidic protein; IL-17, interleukin-17; LFB, luxol fast blue; LncRNA, long non-coding RNA; MCP-1, monocyte chemoattractant protein-1; MOG, myelin oligodendrocyte glycoprotein; MS, multiple sclerosis; NC, negative control; shRNA, short hairpin RNA; TGF-β, transforming growth factor-β; TNF-α, tumor necrosis factor-α; TRAP1, TGF-β receptor-associated protein 1.
1 | INTRODUCTION

Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE) are a central nervous system (CNS) demyelinating disease accompanied by chronic inflammation and axonal degradation, mainly resulting from an autoimmune attack on the white matter (Faisser et al., 2019; Hafler, 2004). Autoreactive CD4+ T effector cells including helper T cell 1 (Th1) and Th17 cell are believed as the major effector cells, which infiltrate into the CNS and initiate MS pathology (Dong & Yong, 2019; Yi et al., 2019). In addition, glial cells are now recognized to be important players contributing to MS (Baecher-Allan et al., 2018; Dong & Yong, 2019; Yi et al., 2019).

Astrocytes are the most abundant glial cells in the CNS, and play a major role in supporting the neural transmission, maintaining the function and the survival of neurons. During the CNS inflammation, astrocytes secrete pro-inflammatory cytokines (i.e., IL-6, TNF-α, MCP-1, and CXCL10) and mediate immune cell infiltration into the CNS, resulting in extending further inflammatory reaction (Giovannoni & Quintana, 2020). Furthermore, astrocytes proliferate and enhance the expression of glial fibrillary acidic protein (GFAP) in an activated process termed reactive astrogliosis, a vital cause of the plaque formation of MS (Dong & Benveniste, 2001; Giovannoni & Quintana, 2020; Nair et al., 2008). In response to interleukin-17 (IL-17), astrocytes are activated to produce a great number of pro-inflammatory cytokines, which aggravates the blood–brain barrier (BBB) damage and facilitates autoimmune T cell and inflammatory cell migration into the CNS (Chen, Liu, & Zhong, 2020; Liu et al., 2014, 2019; Tzartos et al., 2008; Yan et al., 2012). Although the accumulating evidence has shown the crucial role of the activated astrocytes in CNS diseases, the mechanisms by which astrocyte activation involved in MS/EAE remains largely unclear.

Transforming growth factor beta (TGF-β) is a pleiotropic cytokine that has been found to be dysregulated in many neurodegenerative disorders, including MS (Diniz et al., 2019; Lee et al., 2017; Parsa et al., 2016). TGF-β signaling is mediated mainly by two serine threonine kinase receptors, TGFβR1 and TGFβRII. Upon binding to TGFβRII, TGF-β triggers phosphorylating Smad2 and Smad3 that in turn bind to Smad4, which then translocates to the nucleus and modulates the expression of target genes (Diniz et al., 2019). Recently, emerging data show that TGF-β signaling is associated with immune-mediated disease, including MS (Lee et al., 2017). In EAE mice, TGF-β/Smad pathway in astrocytes is activated to promote the release of inflammatory factors resulting in an inflammatory microenvironment and to exacerbate EAE pathology (Diniz et al., 2019; Parsa et al., 2016; Yoshida et al., 2014). Conversely, blocking TGF-β decreases the infiltration of inflammatory lymphocytes into the CNS and improves the pathogenesis of EAE (Lee et al., 2017). Of important, experimental evidence reveal that TGF-β receptor-associated protein 1 (TRAP1) has been identified as a specific molecular chaperone for interaction of Smad4 that is an essential protein for TGF-β signaling activation (Wurthner et al., 2001). However, the functions and mechanisms of TRAP1 in modulating inflammatory response in astrocytes remains to be determined.

Long noncoding RNAs (lncRNAs) are transcripts that are more than 200 nucleotides in length but are not protein-coded. Numerous studies have identified that lncRNAs play key roles in a plethora of cellular processes, including chromatin remodeling, RNA stability, gene transcription, protein translation, and immune response (Kopp & Mendell, 2018; Ransohoff et al., 2018; St Laurent et al., 2015). LncRNAs positively or negatively regulate the expression of some genes by interacting with chromatin-modifying complexes to modulate the epigenetic landscape of chromatin (Ransohoff et al., 2018). LncRNAs interact with a large number of epigenetic modifier complexes such as PRC2, PRC1, Tip60/P400, ESET, and HDAC1 (Guttmann et al., 2011; Khalil et al., 2009). In addition, some research report that a few lncRNAs interact with histone acetyltransferase P300 and nuclear transcription factor kappa B (NF-kB) to regulate the expression of genes (Chen, Dong, et al., 2020; Li et al., 2018). It is confirmed that lncRNAs contribute to some neurodegenerative diseases, including MS (Wan et al., 2017; Zhang et al., 2016). However, the mechanisms that how lncRNAs regulate the activated astrocytes in MS/EAE process remain largely unknown.

In the present study, we found that TRAP1/Smad pathway was activated both in the spinal cord tissue of EAE mice (in vivo) and in the astrocytes stimulated with IL-17 (in vitro). We analyzed lncRNA AK018453, an up-regulated lncRNA in IL-17-activated astrocytes, and further determined its function and mechanism in regulating TRAP1/Smad pathway, the production of pro-inflammatory cytokines and demyelination lesions of EAE mice. Our data indicated that AK018453 promoted TRAP1 expression through interaction with CBP/P300, which was enriched in the promoter of TRAP1 and triggered Smad signaling, resulting in the production and release of pro-inflammatory cytokines and chemokines in large amounts in the IL-17-stimulated astrocytes. Knockdown of both TRAP1 and AK018453 downregulated the production of pro-inflammatory cytokines in astrocytes and ameliorated the pathogenesis of EAE. Our findings suggest that targeting certain lncRNAs in astrocytes might be a potential strategy for clinical treatment of MS.

2 | MATERIALS AND METHODS

2.1 | Animal, antibodies and reagents

C57BL/6 mice (Shanghai Experimental Animal Center, Chinese Academy of Sciences) were bred and housed under specific pathogen-free (SPF) conditions. All experimental procedures were approved by
the Institutional Animal Use Committee of Chinese Academy of Sciences. The reagents were used in this study: anti-GFAP antibody (Rabbit, ab7260, Abcam), anti-GFAP antibody (Mouse, ab4648, Abcam), anti-TRAP1 antibody (Rabbit, CL647-10325, Proteintech), anti-TGFβRII antibody (Rabbit, ab61213, Abcam), anti-p-Smad2/3 antibody (Rabbit, 8828, Cell Signaling Technology), anti-Smad2/3 antibody (Rabbit, 3102, Cell Signaling Technology), anti-Smad4 antibody (Rabbit, 9515, Cell Signaling Technology), anti-NF-κB p65 antibody (Rabbit, 8242, Cell Signaling Technology), anti-CBP/P300 antibody (Rabbit, 17-620, Sigma Aldrich), anti-RNA Pol II antibody (Mouse, ab7260, Abcam), anti-GFAP antibody (Mouse, ab4648, Abcam), anti-p-Smad2/3 antibody (Rabbit, 3102, Cell Signaling Technology), anti-Smad4 antibody (Rabbit, 9515, Cell Signaling Technology), anti-NF-κB p65 antibody (Rabbit, 8242, Cell Signaling Technology), anti-CBP/P300 antibody (Rabbit, 17-620, Sigma Aldrich), anti-hH3K27ac antibody (Rabbit, ab177178, Abcam), the secondary antibodies (Sigma Biotechnology), Myelin oligodendrocyte glycoprotein (MOG) amino acids 35–55 (MOG35–55 peptides, MEVGWYRSPFSRVVHLNYRNGK) (China Peptides Co. Ltd), recombinant mouse IL-17 (R&D Systems), and ELISA kits (BD Biosciences).

2.2 | EAE induction and clinical evaluation

EAE mice model was performed as previously described (Liu et al., 2014, 2019). Briefly, C57BL/6 female mice with age of 6–8 weeks were immunized with MOG35–55 (300 μg) emulsified in complete Freund’s adjuvant (Sigma Aldrich) containing 5 mg/ml of Mycobacterium tuberculosis (H37Ra strain, Difco). On day 0 and day 2, mice were intraperitoneally injected pertussis toxin (200 ng, Invitrogen), then monitored daily for clinical scores of EAE. The PBS was injected into mice as the negative control (NC).

2.3 | Primary astrocyte culture

Primary mouse astrocytes were cultured as described previously (Liu et al., 2014, 2019, 2021). Astrocytes were synchronized with non-serum culture media for 12–16 h prior to IL-17 treatment.

2.4 | Real-time PCR assay

The extraction of total RNAs from the spinal cords of mouse or astrocytes and real-time PCR assay were carried out as described previously (Liu et al., 2019). The levels of gene transcription were calculated with the 2−ΔΔCT method. The primers are listed in the Table S1.

2.5 | Detection and analysis of lncRNA profiles

The lncRNA expression profiles were detected as previously described (Liu et al., 2018; Zhou et al., 2018). In brief, Mouse LncRNA Microarray v2.0 (8 × 60K, Arraystar) was performed by Kangchen Bio-tech (Shanghai, China) to measure the global profiling of mouse lncRNAs in primary mouse astrocytes treated with or without IL-17. Total 31,423 lncRNAs and 25,376 coding transcripts are detected by second-generation microarray.

RNAs from astrocytes (50 ng/ml of IL-17 treatment at 0, 3, and 6 h) were to run microarray analysis as previously described (Liu et al., 2018; Zhou et al., 2018). The acquired raw array images were processed using Agilent Feature Extraction software (version 11.0.1.1), and then normalized and analyzed by the GeneSpring GX v12.0 software package (Agilent Technologies). Differentially expressed IncRNAs were then demonstrated through fold-change as well as p values calculated with t-test. The threshold for up- and down-regulation was fold change >2.0 and p value <.05.

2.6 | Enzyme-linked immunosorbent assay (ELISA)

ELISA was applied according to the manufacturer’s instructions. Briefly, the serum of mice or the supernatant of cultured astrocytes was collected to detect the secretion level of TGF-β, TNF-α, monocyte chemoattractant protein-1 (MCP-1) and C-X-C motif chemokine 10 (CXCL10).

2.7 | Western blot assay

As described previously (Liu et al., 2019), the total protein was extracted from the spinal cords of mouse as well as the cultured astrocytes. The expression level of protein in samples was normalized by GAPDH protein.

2.8 | Co-immunoprecipitation (Co-IP) assay

Co-IP assay was performed to assess the interaction between TRAP1 and Smad4 as described (Ma et al., 2019). Briefly, the lysates of cell or tissue in IP lysis buffer (pH 7.4, 0.025 M Tris, 0.15 M NaCl, 0.001 M EDTA, 1% NP40, and 5% glycerol) were incubated with anti-TRAP1 (2 μg), anti-Smad4 (2 μg) or IgG (2 μg) overnight at 4°C with shaking. The immune complex was incubated with protein A/G beads for 2 h at room temperature with mixing and then washed to remove the unbound immune complex. Finally, the bound immune complex was dissociated from the beads with 5× loading buffer to perform Western blotting assay.

2.9 | Immunofluorescence assay (IFA)

Protein expression was performed by the immunofluorescence assay (IFA) as previously described (Zhou et al., 2019).

2.10 | Lentivirus generation

The lentivirus vector system contains the basic element of HIV, 5’ LTR and 3’ LTR and other auxiliary components, such as WPRE (woodchuck hepatitis virus post transcriptional regulatory element). Recombinant lentiviral vectors carrying with EGFP and with astrocyte-specific promoter of GFAP (Liu et al., 2019, 2021) were
constructed by Gene Chem (Shanghai, China), which can cross the blood-brain barrier. To silence the mouse TRAP1 and IncRNA AK018453, shRNA sequences against them were designed. shRNA sequences were as followed: sh-Ctrl, 5′-TTC TCC GAA CGT GTC ACG T-3′; sh-AK018453, 5′-GGG CAG TTC CAC TCA CTT CTT-3′; sh-TRAP1, 5′-ACT CTA TAA CCC TGG TTA A-3′.

2.11 | RNA immunoprecipitation (RIP) assay

RIP assay was performed as previously described (Liu et al., 2021; Tsai et al., 2010). Briefly, after stimulating with IL-17 (50 ng/ml), primary mouse astrocytes were treated with 0.3% formaldehyde in DMEM/F12 medium for 10 min at 37°C. Glycine was dissolved in PBS for 5 min at room temperature. The cell pellets were resuspended in RIPA buffer, incubated on ice with frequent vortex for 30 min, and then the lysate was centrifugated. Antibodies were added and incubated for 4 h at 4°C. The beads were resuspended in RIPA buffer and treated with proteinase K. Then, RNA samples were extracted with Trizol reagent. Co-precipitated RNAs were purified by RNAasy Mini Kit and detected with qPCR assay. The data of retrieved RNAs is calculated from the subtraction of RT/input ratio and non-RT/input ratio. The primers for RIP assay were listed in the Table S1.

2.12 | Chromatin immunoprecipitation (ChIP) assay

ChIP assay was used as described previously (Liu et al., 2021; Tsai et al., 2010). Briefly, primary mouse astrocytes were stimulated with or without IL-17 for 6 h, then cells were treated with 1% formaldehyde, and stopped by 1.25 mM of glycine. The antibodies used in ChIP assay were anti-NF-κB p65 antibody, anti-H3K27ac antibody, anti-Pol II antibody, anti-CBP/P300 antibody, and normal mouse IgG. All immunoprecipitated chromatin DNA was analyzed by qPCR. The primers for ChIP assay were listed in the Table S1.

2.13 | Histopathology assay

Histopathology assay was applied as previously described (Liu et al., 2014, 2019). Hematoxylin and eosin (H&E) and luxol fast blue (LFB) staining on 4 μm paraffin-embedded spinal cord sections were performed to evaluate inflammation and demyelination, respectively. For immunofluorescent assay (IFA), frozen sections (10 μm) from spinal cord were incubated with anti-GFAP antibody and anti-TRAP1 antibody. Furthermore, the ultrastructural of spinal cords were observed under electron microscope (EM).

2.14 | Statistical analysis

Statistical analysis was performed by GraphPad Prism version 5.0 software with the two-tailed unpaired Student’s t test or one-way multiple-range analysis of variance (ANOVA). A Mann–Whitney test was used for nonparametric data (EAE scoring). Data presented as mean ± standard error of mean (SEM), calculated for all points from at least three independent experiments in triplicates. Values of p < .05 was considered significant.

3 | RESULTS

3.1 | TRAP1/Smad pathway is activated and inflammatory response is upregulated in EAE mice

To determine whether the TRAP1/Smad pathway is activated in EAE, we firstly analyzed the expression of TRAP1 and the activation of TGF-β/Smad pathway in spinal cords tissues. As shown in Figure 1a, the mRNA levels of TGF-β1, TRAP1 and TGFβRII were evidently increased by real-time PCR assay in EAE mice, comparing with negative control (NC) mice. Then, Western blot assay was used to measure the protein expression of TRAP1, TGFβRII, Smad4, p-Smad2/3, and GFAP. The results indicated that the levels of TRAP1, TGFβRII, and GFAP proteins were obviously elevated in the spinal cords of EAE mice (Figure 1b). Furthermore, the expression of Smad4 and the phosphorylation level of Smad2/3 (p-Smad2/3) were markedly upregulated in EAE mice (Figure 1b). To further investigate the expression of TRAP1 protein in astrocytes, immunofluorescence assay (IFA) was employed to test TRAP1 co-expression in GFAP positive cells. The results indicated that the protein expression of TRAP1 was significantly increased in GFAP-positive cells (Figure 1c). Finally, the levels of mRNA transcription and secretion of pro-inflammatory cytokines (TNF-α, CXCL10, and MCP-1) in the spinal cords and peripheral blood of EAE mice were assessed by real-time PCR assay and ELISA, respectively. The results showed that mRNA transcription and secretion levels of TNF-α, CXCL10 and MCP-1 were dramatically increased along with the EAE process (Figure 1d,e). These results suggest that TRAP1/Smad pathway is activated in the reactive astrocytes, which was associated with the production of pro-inflammatory cytokines and chemokines in the spinal cords of EAE mice.

3.2 | IL-17 activates TRAP1/Smad pathway and promotes the production of pro-inflammatory cytokines in astrocytes

Our and other groups have documented that IL-17 is a key mediator in regulating autoimmune responses in MS/EAE through the production of a large number of inflammatory cytokines in astrocytes (Balasa et al., 2020; Kuo et al., 2020; Liu et al., 2019). To investigate the possible roles of IL-17 in the activation of Smad pathway and the production of pro-inflammatory cytokines, primary mouse astrocytes were stimulated with IL-17 (50 ng/ml) in serum-free media. First, real-time PCR assay was used to measure the levels of TRAP1 and TGFβRII mRNA transcripts. As shown in Figure 2a, the mRNA level of TRAP1 and TGFβRII was significantly elevated in the astrocytes with IL-17
stimulation at 3 and 6 h. Then, Western blot assay was used to analyze the protein expression of TRAP1, TGFβRII, Smad4, p-Smad2/3, and GFAP. The results showed that the protein level of TRAP1, TGFβRII, Smad4, and GFAP was dramatically increased at 6 h in the astrocytes treated with IL-17 (Figure 2b). Moreover, the expression of Smad4 and p-Smad2/3 was increased at 3 h and lasted for 24 h after IL-17 stimulation (Figure 2b). It is interesting that the interaction of TRAP1 with Smad4 protein was increased in astrocytes by IL-17 at 6 h (Figure 2c). In addition, the mRNA and protein level of TGF-β1 was up-regulated in the astrocytes with IL-17 stimulation at 6 and 12 h, respectively (Figure 2d,e). Finally, the mRNA and protein levels of pro-inflammatory cytokines such as TNF-α, CXCL10, and MCP-1 were simultaneously upregulated and peaked at 6 or 12 h in the astrocytes stimulated by IL-17 (Figure 2d,e), respectively. These data suggest that IL-17 triggers Smad signal and enhances the production of pro-inflammatory cytokines in astrocytes.

3.3 Knockdown TRAP1 inhibits inflammatory response in IL-17-activated astrocytes

To further verify whether TRAP1 regulates inflammatory responses in astrocytes by IL-17, lentivirus of TRAP1-shRNA (TRAP1-shRNA) specifically targeting astrocytes was generated, and then infected primary mouse astrocytes. As shown in Figure 3a, TRAP1 protein was
significantly decreased in TRAP1-shRNA group, compared with Ctrl-shRNA group. Meanwhile, p-Smad2/3, and Smad4 were dramatically decreased from TRAP1-shRNA group in astrocytes stimulated with IL-17 (50 ng/ml) (Figure 3a). Importantly, TRAP1 knockdown significantly inhibited the TRAP1 interaction with Smad4 in astrocytes treated with IL-17 (Figure 3b). Moreover, the production of pro-inflammatory cytokines of TNF-α, CXCL10, and MCP-1 was markedly reduced in TRAP1-shRNA astrocytes compared to Ctrl-shRNA ones (Figure 3c,d). These results indicate that IL-17-mediated the upregulation of TRAP1 is associated with the production of pro-inflammatory cytokines in astrocytes.

3.4 Knockdown of TRAP1 alleviates EAE pathogenesis in mice

To further explore the role of TRAP1 in the pathogenesis of EAE, 1 x 10⁷ TU of lentivirus specifically targeting astrocytes with TRAP1-shRNA (TRAP1-shRNA) was injected into mice via the tail vein, and lentivirus containing Ctrl-shRNA as shRNA control. After 7 days, EAE mice was immunized by MOG35–55. The clinical score indicated that TRAP1 knockdown not only suppressed the onset of EAE but also relieved illness (Figure 4a). Meanwhile, the protein level of TRAP1, Smad4, p-Smad2/3, and GFAP was markedly decreased in the spinal cords of EAE mice in TRAP1-shRNA group compared with Ctrl-shRNA control mice (Figure 4b). The levels of pro-inflammatory cytokines of TNF-α, CXCL10, and MCP-1 were significantly downregulated in TRAP1-shRNA group compared with Ctrl-shRNA control mice (Figure 4c,d). Furthermore, H&E and LFB staining showed that the EAE mice in TRAP1-shRNA possessed less inflammatory cell infiltration and demyelination lesion in the spinal cords, while Ctrl-shRNA mice had more inflammatory cell infiltration and more severer demyelination lesions (Figure 4e,f). Specifically, the myelin sheath of the spinal cords in Ctrl-shRNA group was disintegrated and damaged under EM, whereas only a slightly loosening of the sheath was shown in TRAP1-shRNA group (Figure 4g). These data suggest that TRAP1 is involved in the activation and hyperplasia of
astrocytes, the infiltration of inflammatory cells and the injury of spinal cords in EAE mice.

### 3.5 The analysis of lncRNA expression profiles in astrocytes treated with IL-17

To investigate whether lncRNAs is involved in regulating inflammatory astrocytes, mouse lncRNA microarray was performed to analyze the change of lncRNA expression profile. As shown in Figure 5a, the Venn Diagrams exhibited that 222 lncRNAs were differentially expressed in primary mouse astrocytes stimulated with IL-17 (50 ng/ml) at 3 and 6 h. Meanwhile, a lncRNA named AK018453 was up-regulated among the differentially-expressed lncRNAs (Figure 5b). Then, real-time PCR assay was used to verify the levels of AK018453 in primary mouse astrocytes treated with IL-17 and in the spinal cord tissues of EAE mice. The results indicated that the level of AK018453 was significantly increased in astrocytes by IL-17 at 3, 6, 12, and 24 h, and in EAE mice with clinical score 2.0, 3.0, and 4.0 (Figure 5c).

### 3.6 LncRNA AK018453 regulates the TRAP1 expression

To explore the role of lncRNA in activated astrocytes and EAE mice, we first analyzed the sequence feature of AK018453. We found that the sequence of AK018453 with 1250 bp in length is the antisense sequence of TRAP1 gene at 4788–6035 locus (Figure S1a,b). The results suggested that AK018453 may regulate the TRAP1 expression.

To this end, RIP assay was utilized to measure the interaction of AK018453 with NF-κB p65 or CBP/P300. As shown in Figure 5d, AK018453 dramatically interacted with NF-κB p65 and CBP/P300 in activated astrocytes in response to IL-17. Of importance, knockdown of AK018453 significantly inhibited the interaction with NF-κB p65.
and CBP/P300 (Figure 5e). Moreover, ChIP assay revealed that NF-κB p65, CBP/P300, H3K27ac, and RNA Pol II were differentially enriched in the TRAP1 gene promoter in astrocytes by IL-17 (Figure 5f). AK018453 knockdown significantly decreased NF-κB p65 and CBP/P300 enrichment in the TRAP1 promoter (Figure 5g). Above data suggest that the interaction of AK018453 with CBP/P300 may be involved in epigenetically regulating the expression of TRAP1 gene.

3.7 | LncRNA AK018453 is essential for TRAP1/Smad pathway activation and pro-inflammatory cytokines production in IL-17-activated astrocytes

To assess the roles of AK018453 in regulating the activation of TRAP1/Smad signal and the production of pro-inflammatory cytokines in activated astrocytes by IL-17, the recombinant lentivirus of AK018453 shRNA (AK-shRNA) specifically targeting astrocytes were
performed to transduce primary mouse astrocytes. As shown in Figure 6a, knockdown of AK018453 suppressed significantly the level of TRAP1 and Smad4 protein, and decreased the phosphorylation of Smad2/3 in astrocytes treated with IL-17 (50 ng/ml). Meanwhile, AK018453 knockdown reduced the interaction of TRAP1 with Smad4 (Figure 6b). In addition, the production of TNF-α, CXCL10, and MCP-1 was reduced in AK-shRNA group (Figure 6c,d). These results suggest that AK018453 regulates TRAP1 expression and Smad signaling to mediate inflammatory response in astrocytes.

3.8 | AK018453 knockdown in astrocytes ameliorates the pathology of EAE mice

To further investigate whether AK018453 in astrocytes is associated with the pathogenesis of EAE, 1 × 10^7 lentiviruses of AK018453 shRNA (AK-shRNA) (Figure 7a) specifically targeting astrocytes was injected into mice via the tail vein, 7 days before EAE induction. As shown in Figure 7b, AK018453 inhibition slowed down significantly EAE progression. Meanwhile, the expression of TRAP1, Smad4, p-Smad2/3, and GFAP was dramatically down-regulated in AK-shRNA group (Figure 7c). Furthermore, AK018453 knockdown decreased markedly the production of TNF-α, CXCL10, and MCP-1 by real-time PCR assay and ELISA (Figure 7d,e). Additionally, H&E and LFB staining displayed that the inflammatory cell infiltration and demyelination lesion in white matter of the spinal cords were diminished in AK-shRNA EAE mice, compared with the Ctrl-shRNA controls (Figure 7f,g). The myelin sheath in Ctrl-shRNA group was disintegrated under EM, whereas only a light loosening of the sheath was observed in AK-shRNA group (Figure 7h). Thus, these data suggest that lncRNA AK018453 is involved in regulating TRAP1/Smad signal pathway, which mediates the reactive astrocytosis, inflammatory response and myelin damage.
4 | DISCUSSION

Over the past decades, lncRNAs have been known as key mediators contributing to multiple cellular events associated with neuroinflammation and neurodegeneration diseases. LncRNAs are abundantly expressed in mammalian CNS allowing a quick response to environmental or molecular changes (Riva et al., 2016), which epigenetically regulates the expression of some genes mainly by chromatin remodeling (Khalil et al., 2009; Ransohoff et al., 2018). In this study, we used lncRNA microarray to analyze differentially-expressed lncRNAs in primary mouse astrocytes by IL-17, and found that the lncRNA AK018453 was highly expressed. AK018453 is homologous partially to the antisense sequence of TRAP1 gene, but few studies have investigated its function and molecular mechanism. We discovered that downregulating the expression of AK018453 resulted in the reduction of IL-17-mediated inflammation and the amelioration of EAE pathogenesis through regulating TRAP1/Smad pathway (Figure 8). Therefore, our findings support the notion that lncRNAs involve in regulating the progression of MS/EAE.

It is now accepted that neuroinflammation is a common feature to almost all neurodegeneration diseases, including MS. In the CNS, reactive astrocytes are vital mediator to construct the detrimental positive-feedback loop of inflammation, which promotes the inflammatory cascades and accelerates neurological disorders (Baecher-Allan et al., 2018). Response to inflammatory stress, reactive astrocytes express a great number of gene involved in inflammation, oxidative stress and BBB disruption (Wang et al., 2019). Accumulating evidence has shown that IL-17 mediates astrocyte activation to produce pro-inflammatory cytokines and chemokines, in turn facilitating immune cells migration to the CNS to aggravate the disruption of BBB and the damage of myelin sheath in the white matter (Chen, Liu, & Zhong, 2020; Liu et al., 2014, 2019; Tzartos et al., 2008; Yan et al., 2012). Herein, our results exhibited that IL-17 increased the expression of GFAP and the secretion of pro-inflammatory cytokines along with the pathological progression of EAE in mice.

TGF-β/Smad pathway regulates immune response and inflammatory processes (Travis & Sheppard, 2014; Veldhoen et al., 2006; Wu et al., 2021), which are clinically critical in MS. Emerging evidence shows that the Smad signaling regulates the development and function of CD4+ T cells in MS lesions, which is associated with MS pathology (Gorelik & Flavell, 2002; Lee et al., 2017). TGF-β and IL-6 have been demonstrated to drive Th17 cell differentiation (Mangan et al., 2006; Veldhoen et al., 2006), and TGF-β and IL-4 also have been shown to drive Th9 cell differentiation in vitro (Veldhoen et al., 2008). Importantly, TGF-β at the side of inflammation, promotes proliferation and cytokine production of Th1 cells to contribute to MS (Lee et al., 2017). However, the understanding of TGF-β/Smad pathway in astrocytes is still very limited. In this study, our data showed that the
high expression of TGF-β, TRAP1, TGFβRII, p-Smad2/3, and Smad4 was consistent with GFAP and pro-inflammatory cytokines production in the spinal cords of EAE mice and in activated astrocytes by IL-17. Meanwhile, the interaction of TRAP1 with Smad4 occurred in EAE (in vivo) and in IL-17-activated astrocytes (in vitro). Of importance, TRAP1 knockdown in astrocytes not only suppressed pro-inflammatory cytokine production both in vivo and in vitro, but also inhibited inflammatory cell infiltration and demyelination lesion in EAE mice. Nevertheless, the underlying function and mechanisms of TRAP1 in astrocytes are far from known in MS/EAE.

Recent studies indicate lncRNAs are involved in multiple biological processes including immune responses. In CNS, lncRNAs contribute to the brain development, neuron function as well as neuroinflammation (Riva et al., 2016; Tripathi et al., 2021; Wu et al., 2013). Accumulating evidence has shown that lncRNAs as key mediators associated with the onset and progression of MS (Sun et al., 2017; Yang et al., 2018; Zhang et al., 2017), but less data focus on the regulation of astrocytes by lncRNAs. Herein, we assumed that IL-17-induced lncRNAs can participate in astrocyte activation, inflammatory response and the pathogeneses of EAE. Our studies indicated that the lncRNA AK018453 is complementary to the sense chain of TRAP1 gene, and was highly-expressed in astrocytes activated by IL-17 and in EAE mice. Knockdown AK018453 inhibited the TRAP1 expression and Smad pathway as well as attenuated reactive inflammatory responses.

**FIGURE 7** AK018453 knockdown lessens the pathology of EAE mice. On day 7 after administration with recombinant lentivirus carrying GFAP promoter and AK-shRNA or ctrl-shRNA sequence, respectively, mice were immunized with or without MOG35–55 for 21 days. (a) The level of IncRNA AK018453 was determined by real-time PCR assay. ***p < .001 versus NC group; #p < .05 versus ctrl-shRNA group (n = 10 mice/group). (b) The clinical scores for EAE mice infected with AK-shRNA or ctrl-shRNA (n = 10 mice per group). ***p < .001 versus NC group; #p < .01 versus ctrl-shRNA group. (c) Western blot assay was used to determine the protein levels of TRAP1, Smad4, p-Smad2/3, Smad2/3, and GFAP in the spinal cords. (d and e) The production of TNF-α, CXCL10, and MCP-1 in the spinal cords and peripheral blood from the AK-shRNA and ctrl-shRNA mice was measured by real-time PCR assay and ELISA assay, respectively. The data are represented as mean ± SEM. ***p < .001 versus NC group; #p < .05, ##p < .01, and ###p < .001 versus ctrl-shRNA group (n = 10 mice/group). (f) Hematoxylin and eosin (H&E) staining was designed to observe the infiltrations of inflammatory cells in spinal cords (scale bars, 50 μm). (g) Luxol fast blue (LFB) staining was utilized to test the medullary sheath damages from spinal cords (scale bars, 50 μm). Red box areas in the upper rows are presented enlarged underneath. (h) Electron microscope (EM) was employed to investigate the severe disruption or mild loosening of the medullary sheath in spinal cords. Red arrow shows the changes of the medullary sheath. Scale bars, 1 μm.
astrocytosis both in vivo and in vitro, resulted in the alleviation of inflammatory response and demyelination lesion in EAE mice. However, it is still unknown about the mechanisms how lncRNAs regulate TRAP1 in astrocytes. Some studies show that lncRNAs epigenetically regulate gene expression via histone modification. lncRNAs are largely associated with the polycomb repressive complex 2 (PRC2) complex, the CoREST/REST complex and the CBP/p300 complex (Khalil et al., 2009; Tsai et al., 2010; Zhou et al., 2018). In this study, we showed that AK018453 interacted with CBP/P300 and NF-xB p65 in the promoter of TRAP1gene to promote TRAP1 expression. These results suggest that lncRNA AK018453 might regulate epigenetically TRAP1 expression to trigger Smad signaling in activated astrocytes and EAE.

Taken together, our present data show that IL-17-induced lncRNA AK018453 contributes to TRAP1 expression via the interaction with CBP/P300 and NF-xB p65, and then activates Smad pathway in astrocytes, which is associated with the production pro-inflammatory cytokines and the pathology of EAE. Therefore, these data support that lncRNAs in astrocytes may be involved in neuroinflammation and pathogenesis of MS.

**AUTHOR CONTRIBUTIONS**

Xiaomei Liu, Feng Zhou, and Ying Yang designed research; Qingxiu Zhang, Ying Yang, Yingyu Chen, Ruixue Lv, Yifan Wang, Xiangyang Li, and Menglu Zhou performed research; Ying Yang, Yingyu Chen, Xiaomei Liu, Feng Zhou, Qian Yu, and Xiaotian Wang analyzed data; Xiaomei Liu, Feng Zhou, Suping Qin, Hongjuan You, Xiaocui Li, Huang Wang, and Qingxiu Zhang drafted and revised the paper.

**ACKNOWLEDGMENTS**

This work was supported by the National Natural Science Foundation of China (81971179 to Xiaomei Liu, 82071304 and 81671149 to Qingxiu Zhang), the Natural Science Foundation of Jiangsu Province (BK20191463 to Xiaomei Liu, BK20211347 to Hongjuan You), Jiangsu Commission of Health (ZZ2019035 to Feng Zhou), Jiangsu Provincial Department of Education (20KJA320004 to Feng Zhou, 21KJA310004 to Hongjuan You), the Jiangsu Graduate Innovation Program (KYCX20_2469 to Menglu Zhou), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (2017 PAPD).

**REFERENCES**

Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018). Multiple sclerosis: Mechanisms and immunotherapy. Neuron, 97(4), 742–768. https://doi.org/10.1016/j.neuron.2018.01.021

Balaia, R., Barcutean, L., Balasa, A., Motatalianu, A., Roman-Filip, C., & Manu, D. (2020). The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Human Immunology, 81(5), 237–243. https://doi.org/10.1016/j.humimm.2020.02.009

Chen, J., Liu, X., & Zhong, Y. (2020). Interleukin-17A: The key cytokine in neurodegenerative diseases. Frontiers in Aging Neuroscience, 12, 566922. https://doi.org/10.3389/fnag.2020.566922

Chen, Z., Dong, W. H., Qiu, Z. M., & Li, Q. G. (2020). The monocyte-derived exosomal CLMAT3 activates the CtBP2-p300-NF-kappaB transcriptional complex to induce proinflammatory cytokines in ALI. Molecular Therapy Nucleic Acids, 21, 1100. https://doi.org/10.1016/j.omtn.2020.07.040

Diniz, L. P., Matias, I., Siqueira, M., Stipursky, J., & Gomes, F. C. A. (2019). Astrocytes and the TGF-beta1 pathway in the healthy and diseased brain: A double-edged sword. Molecular Neurobiology, 56(7), 4653–4679. https://doi.org/10.1007/s12035-018-1396-y

Dong, Y., & Benveniste, E. N. (2001). Immune function of astrocytes. Glia, 36(2), 180–190. https://doi.org/10.1002/glia.1107

Dong, Y., & Yong, V. W. (2019). When encephalitic T cells collaborate with microglia in multiple sclerosis. Nature Reviews. Neurology, 15(12), 704–717. https://doi.org/10.1038/s41582-019-0253-6

Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019). Progressive multiple sclerosis: From pathophysiology to therapeutic strategies. Nature Reviews. Drug Discovery, 18(12), 905–922. https://doi.org/10.1038/s41573-019-0035-2
Liu, X., Zhang, Q., Wang, W., Niu, L., Li, X., Hu, H., Zhang, B., Kou, Y., Guo, J., Kong, F., Pan, W., Gao, D., Meves, J. M., Sun, H., Xue, M., Zhang, Q., Wang, Y., & Tang, R. (2019). MiR-409-3p and MiR-1896 co-operatively participate in IL-17-induced inflammatory cytokine production in astrocytes and pathogenesis of EAE mice via targeting SOCS3/STAT3 signaling. Glia, 67(1), 101–112. https://doi.org/10.1002/glia.23530
autoimmunity by preventing IFN-gamma-induced hyperactivation of astrocytes. The EMBO Journal, 38(10), e100947. https://doi.org/10.15252/embj.2018100947

Wu, B., Zhang, S., Guo, Z., Bi, Y., Zhou, M., Li, P., Seyedsadr, M., Xu, X., Li, J. L., Markovic-Plese, S., & Wan, Y. Y. (2021). The TGF-beta superfamily cytokine Activin-a is induced during autoimmune neuroinflammation and drives pathogenic Th17 cell differentiation. Immunity, 54(2), 308–323.e6. https://doi.org/10.1016/j.immuni.2020.12.010

Wu, P., Zuo, X., Deng, H., Liu, X., Liu, L., & Ji, A. (2013). Roles of long non-coding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Research Bulletin, 97, 69–80. https://doi.org/10.1016/j.brainresbull.2013.06.001

Wurthner, J. U., Frank, D. B., Felici, A., Green, H. M., Cao, Z., Schneider, M. D., McNally, J., Lechleider, R. J., & Roberts, A. B. (2001). Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone. The Journal of Biological Chemistry, 276(22), 19495–19502. https://doi.org/10.1074/jbc.M006473200

Yan, Y., Ding, X., Li, K., Ciric, B., Wu, S., Xu, H., Gran, B., Rostami, A., & Zhang, G. X. (2012). CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Molecular Therapy, 20(7), 1338–1348. https://doi.org/10.1038/mt.2012.12

Yang, X., Wu, Y., Zhang, B., & Ni, B. (2018). Noncoding RNAs in multiple sclerosis. Clinical Epigenetics, 10(1), 149. https://doi.org/10.1186/s13148-018-0586-9

Yi, W., Schluter, D., & Wang, X. (2019). Astrocytes in multiple sclerosis and experimental autoimmune encephalomyelitis: Star-shaped cells illuminating the darkness of CNS autoimmunity. Brain, Behavior, and Immunology, 80, 10–24. https://doi.org/10.1016/j.bbi.2019.05.029

Yoshida, Y., Yoshimi, R., Yoshih, H., Kim, D., Dey, A., Xiong, H., Munasinghe, J., Yazawa, I., O’Donovan, M. J., Maximova, O. A., Sharma, S., Zhu, J., Wang, H., Morse, H. C., 3rd, & Ozato, K. (2014). The transcription factor IRF8 activates integrin-mediated TGF-beta signaling and promotes neuroinflammation. Immunity, 40(2), 187–198. https://doi.org/10.1016/j.immuni.2013.11.022

ZHANG ET AL.